-
Je něco špatně v tomto záznamu ?
Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries
R. Mezencev, M. Švajdler,
Jazyk angličtina Země Japonsko
Typ dokumentu časopisecké články
- MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prsu epidemiologie metabolismus patologie chirurgie MeSH
- program SEER MeSH
- radikální mastektomie MeSH
- receptory pro estrogeny metabolismus MeSH
- rizikové faktory MeSH
- sekundární malignity epidemiologie metabolismus patologie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Women diagnosed with breast cancer display higher propensity to develop second primary cancer in the contralateral breast (CBC). Identification of patients with increased risk of CBC and understanding relationships between hormone receptor (HR) statuses of the first and second breast cancers is desirable for endocrine-based prevention strategies. METHODS: Using 1992-2012 data from 13 SEER registries, the risk of developing CBC was determined as ratio of observed and expected second breast cancers (SIR). Association between HR statuses was examined by exploratory data analysis and multivariable logistic regression. RESULTS: Women with ER-positive and ER-negative breast cancers have increased risk of developing CBC with SIR values 2.09 (CI 95 = 1.97-2.21) and 2.40 (CI 95 = 2.18-2.63), respectively. ER statuses of the CBC are moderately positively associated. In metachronous CBC, most cases with ER-positive first cancers had ER-positive second breast cancers (81.6 %; CI 95 = 80.2-82.9 %); however, considerable proportion of cases with ER-negative first cancers had ER-positive second cancers (48.8 %; CI 95 = 46.2-51.4 %). CONCLUSIONS: Some women with ER-negative breast cancers may benefit from endocrine-based prevention of ER-positive CBC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031523
- 003
- CZ-PrNML
- 005
- 20171122123847.0
- 007
- ta
- 008
- 171025s2017 ja f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12282-016-0716-1 $2 doi
- 035 __
- $a (PubMed)27502779
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Mezencev, Roman $u Integrated Cancer Research Center, School of Biology and Parker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, 310 Ferst DR, Atlanta, GA, 30329, USA. rmezencev3@gatech.edu.
- 245 10
- $a Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries / $c R. Mezencev, M. Švajdler,
- 520 9_
- $a BACKGROUND: Women diagnosed with breast cancer display higher propensity to develop second primary cancer in the contralateral breast (CBC). Identification of patients with increased risk of CBC and understanding relationships between hormone receptor (HR) statuses of the first and second breast cancers is desirable for endocrine-based prevention strategies. METHODS: Using 1992-2012 data from 13 SEER registries, the risk of developing CBC was determined as ratio of observed and expected second breast cancers (SIR). Association between HR statuses was examined by exploratory data analysis and multivariable logistic regression. RESULTS: Women with ER-positive and ER-negative breast cancers have increased risk of developing CBC with SIR values 2.09 (CI 95 = 1.97-2.21) and 2.40 (CI 95 = 2.18-2.63), respectively. ER statuses of the CBC are moderately positively associated. In metachronous CBC, most cases with ER-positive first cancers had ER-positive second breast cancers (81.6 %; CI 95 = 80.2-82.9 %); however, considerable proportion of cases with ER-negative first cancers had ER-positive second cancers (48.8 %; CI 95 = 46.2-51.4 %). CONCLUSIONS: Some women with ER-negative breast cancers may benefit from endocrine-based prevention of ER-positive CBC.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádory prsu $x epidemiologie $x metabolismus $x patologie $x chirurgie $7 D001943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a radikální mastektomie $7 D015409
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a sekundární malignity $x epidemiologie $x metabolismus $x patologie $7 D016609
- 650 _2
- $a receptory pro estrogeny $x metabolismus $7 D011960
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a program SEER $7 D018426
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Švajdler, Marián $u The Faculty of Medicine and Faculty Hospital in Pilsen, Šikl's Department of Pathology, Charles University in Prague, Pilsen, Czech Republic. Bioptická laboratoř, s.r.o., Pilsen, Czech Republic.
- 773 0_
- $w MED00173013 $t Breast cancer (Tokyo, Japan) $x 1880-4233 $g Roč. 24, č. 3 (2017), s. 400-410
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27502779 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171122124007 $b ABA008
- 999 __
- $a ok $b bmc $g 1255116 $s 992550
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 24 $c 3 $d 400-410 $e 20160808 $i 1880-4233 $m Breast cancer $n Breast Cancer $x MED00173013
- LZP __
- $a Pubmed-20171025